DEA Update on Scheduling Synthetic Cannabinoids in Schedule I
The DEA scheduling synthetic cannabinoids update highlights the placement of four novel compounds into Schedule I. These synthetic cannabinoids pose significant public health risks due to their high potency and unknown safety profiles. Clinicians should…
Cannabis News Digest: Clinical Analysis of 12 Articles June 2026
This cannabis news digest reviews 12 articles from June 14, 2026, examining cannabis industry developments, regulatory changes, and enforcement actions. Dr. Caplan provides clinical commentary on the fragmented landscape affecting patient care. The…
DEA Places Four Synthetic Cannabinoids in Schedule I
The Drug Enforcement Administration has placed four synthetic cannabinoids into Schedule I due to their high abuse potential and lack of accepted medical use. These DEA Schedule I synthetic cannabinoids include 4F-MDMB-BUTICA, ADB-4en-PINACA,…
Policy Watch: 20 Synthetic Substances Regulatory Updates — May 13, 2026
This update covers synthetic substances regulatory updates 2026 with 20 key DEA scheduling actions. These include synthetic cannabinoids, opioids, and benzodiazepine analogs. The regulatory changes highlight challenges for clinicians managing cannabis…
IIPR and Cannabis Reform: 280E Relief and Schedule III Upside – April 16, 2026
Schedule III cannabis reclassification could transform federal policy by easing research restrictions and providing 280e tax relief. This change may improve clinical access and reduce costs for medical cannabis businesses. Patients and clinicians should…
Wildings in Newport: From Grand Store to Illicit Cannabis Farm
Illicit cannabis farm safety risks are significant in Newport, Wales, where a grand department store was converted into an unregulated cannabis cultivation site. These illicit operations lack quality control and pose contamination dangers. Patients must…
Cannabis Europa Conference Highlights European Market Surge
European cannabis market consolidation is accelerating growth and regulatory clarity. Cannabis Europa's London event highlights this surge in medical cannabis development. Clinicians should watch for improved product standardization and clinical research.
More than 350 Cannabis Plants Seized in Kalgoorlie Home
Cannabis law enforcement actions in Kalgoorlie underscore the disconnect between regulatory frameworks and patient access to medicinal cannabis. Over 350 cannabis plants were seized from a residential property, illustrating enforcement under current…
CBD Gummies for Lung Issues: What the Evidence Shows and How They Fit Into Daily Wellness
Patients often inquire about cbd gummies lung issues evidence, but current clinical data is limited. Understanding what the evidence shows is crucial for safe use. This article reviews the scientific findings and their implications for daily wellness.
Dog CBD Anxiety Gummies: What Pet Owners Need to Know Before Trying Them
Veterinary CBD anxiety research is an emerging field with limited clinical data. Pet owners increasingly seek CBD gummies for dog anxiety despite regulatory challenges. Understanding safety and dosing is essential before trying these products.